Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy

NEXT STORY
Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
PREV STORY
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

author_avatar
NASDAQ Market News

Tabula Rasa HealthCare’s Dr. Sandra Leal is President-elect American Pharmacists Association

author_avatar
NASDAQ Market News

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019

author_avatar
NASDAQ Market News